Contact this trialFirst, we need to learn more about you.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Tirzepatide for Heart Failure and Obesity
Recruiting1 awardPhase 3
Torrance, California
This trial is testing a medication called Tirzepatide to see if it can help people who have a certain type of heart failure and are also obese. The medication aims to control blood sugar and reduce weight, which may improve their heart condition. Tirzepatide is developed by Eli Lilly and is under investigation for chronic weight management and other conditions.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service